Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 7, 2002, Pages 615-621

  Malyszko, Jolanta ^a   Malyszko, J S ^a   Mysliwiec, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Adhesion molecules; Coagulation; Endothelial cell injury; Nephrotic syndrome; Protein Z; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ALBUMIN; CELL ADHESION MOLECULE; CHOLESTEROL; CREATININE; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PLASMA PROTEIN; PLASMIN; PROTEIN C; PROTHROMBIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; BIOLOGICAL MARKER; PLASMA PROTEIN Z;

ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; KIDNEY DISEASE; NEPHROTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; THROMBOEMBOLISM; ADULT; ARTERIOSCLEROSIS; BLOOD; CASE CONTROL STUDY; HEMOSTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ADULT; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; MIDDLE AGED; NEPHROTIC SYNDROME; RISK FACTORS; THROMBOEMBOLISM;

EID: 0036775077     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200210000-00006     Document Type: Article

References (46)

1. Llach F. Hypercoagulability, renal vein thrombosis in the nephrotic syndrome. Kidney Int 1985; 28: 429-439.
2. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal failure. Kidney Int 1994; 46: 287-296.
3. Alkjaersig N, Fletcher AP, Narayanan M, Robson AM. Course and resolution of the coagulopathy in nephrotic children. Kidney Int 1987; 31: 772-778.
4. Machleid C, Mettang T, Starz E, Weber J, Risler T, Kuhlmann K. Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Int 1989; 36: 1119-1124.
5. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow condition. J Clin Invest 1994; 93: 204-211.
6. Panicucci F, Sagripanti A, Vispi M, Pinori E, Lecchini L, Barsotti G, Giovanett S. Comprehensive study of hemostasis in nephrotic syndrome. Nephron 1983; 33: 9-13.
7. Vaziri ND, Bremson HE, Ness R. Changes of coagulation factors IX, VIII, VII, X and V in nephrotic syndrome. Am J Med 1980; 280: 168-171.
8. Kauffman RH, Veltkamp JJ, Tilburg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65: 607-613.
9. Thompson C, Forbes CD, Prentice CRM, Kennedy AC. Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med 1974; 43: 339-407.
10. Malyszko J, Malyszko J, Pawlak D, Pawlak K, Mysliwiec M, Rydzewski A, Buczko W. A comprehensive study on platelet function, fibrinolysis, peripheral serotonergic system and serum lipids in nephrotic syndrome. Pol J Pharmacol 1996; 48: 191-195.
11. Malyszko JS, Malyszko J, Mysliwiec M. Tissue factor and tissue factor pathway inhibitor in patients with nephrotic syndrome. Pol Arch Med Wewn 1999; 4: 21-25.
12. Ariens RAS, Moia M, Rivolta E, Ponticelli C, Mannucci PM. High levels of tissue factor inhibitor in patients with nephritic proteinuria. Thromb Haemost 1999; 82: 1020-1023.
13. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-391.
14. Bajzar L, Nesheim ME, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2793-2798.
15. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
16. Blann AD. Endothelial cell activation, injury, damage and dysfunction: Separate entities or mutual terms? Blood Coagul Fibrinolysis 2000; 11: 623-630.
17. Phipps RP. Atherosclerosis: The emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000; 97: 6930-6932.
18. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, Takada A. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994; 75: 569-576.
19. Blann AD, Hopkins J, Winkles J, Wainwright AC. Plasma and serum von Willebrand factor antigen levels in connective tissue disorders. Ann Clin Biochem 1992; 29: 67-71.
20. Stenberg PE, McEver RP, Shuman MA, Jaques YV, Bainton DF. A platelet alpha granule membrane protein (GMP140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-886.
21. Wagner DD. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993; 74: 626-630.
22. Blann AD, Lip GYH. Hypothesis: Is soluble Pselectin a new marker of platelet activation? Atherosclerosis 1997; 128: 135-138.
23. Ishiwata N, Takio K, Katayama M, Watanabe K, Titani K, Ikeda Y, Handa M. Altenatively spliced isoform of P-selectin is present in vivo as soluble molecule. J Biol Chem 1994; 38: 23708-23715.
24. Gearing AJH, Hemingway I, Piggott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules. E-selectin, ICAM-1 and VCAM1: Pathological significance. Ann NY Acad Sci 1992; 667: 324-331.
25. Zucker S, Mirza H, Conner CE. Vascular endothelial growth factor induces tissue factor and matrix metaloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase-A activation and cell proliferation. Int J Cancer 1998; 75: 780-785.
26. Blann AD, Belgore FM, Constans J, Conri C, Lip GYH. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin and fenofibrate. Am J Cardiol 2001; 87: 1160-1163.
27. Blann AD, Lip GYH. The endothelium in atherothrombotic disease: Assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis 1998; 9: 297-306.
28. Karmann K, Min W, Fanslow WC, Pober JS. Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. J Exp Med 1996; 184: 173-182.
29. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD 40. Thromb Haemost 1998; 80: 1008-1014.
30. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 11: 2511-2516.
31. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
32. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
33. Gresele P, Momi S, Berrettini M, Nenci CG, Schwartz HP, Semeraro N, Colucci M. Activated human protein C prevents thrombin-induced thromboembolism in mice. J Clin Invest 1998; 101: 667-676.
34. Kluft C, Meijer P, Biasucci LM, Meo A, Vitrella G, Liuzzo G, Maseri A. Plasma levels of TAFI are elevated in patients with unstable angina pectoris (UAP) compared to stable angina pectoris but show no relationship with outcome of UAP [abstract]. XVII Congress of International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; suppl.: A784.
35. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638-642.
36. Hryszko T, Malyszko J, Malyszko JS, Brzósko S, Pawlak K, Mysliwiec M. A possible role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol Dial Transplant 2001; 16: 1592-1596.
37. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Simvastatin affects TAFI and thrombomodulin in CAPD patients. Thromb Haemost 2001; 86: 900-901.
38. Puccetti L, Bruni F, Pasqui AL, Pastorelli M, Bova G, Cercignani M, et al. TAFI activity is the main determinant of fibrinolysis in hypercholesterolemic subjects [abstract]. XVII Congress of International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; suppl.: A2026.
39. Pabinger-Fashing I, Lechner K, Niessner H, Schmidt P, Balzar E, Mannhalter CH. High levels of plasma protein C in nephrotic syndrome. Thromb Haemost 1985; 53: 5-7.
40. Soff GA, Sica DA, Marlar RA, Evans HJ, Qureshi GD. Protein C levels in nephritic syndrome: Use of a new enzyme-linked immunosorbent assay for protein C antigen. Am J Hematol 1986; 22: 43-49.
41. Du XH, Glass-Greenvalt P, Kant KS, Allen CM, Hayes S, Pollack VE. Nephrotic syndrome with renal vein thrombosis. Pathogenic importance of plasmin inhibitor (alpha2antiplasmin). Clin Nephrol 1985; 20: 186-191.
42. Broze GJ. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86: 8-13.
43. Han X, Fiehler R, Broze GJ. Characterization of the protein Z-dependent protease inhibitor. Blood 2000; 96: 3049-3055.
44. Yin ZF, Huang ZF, Cui J, Fiehler R, Lasky N, Ginsburg D, Broze GJ. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci USA 2000; 97: 6734-6738.
45. Steffano B, Forastiero R, Martinuzzo M, Kordich L. Low plasma protein Z levels in patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis 2001; 12: 411-412.
46. Undar I, Karadogan I, Ozturk F. Plasma protein Z levels inversely correlate with plasma interleukin-6 in patients with acute leukemia and non-Hodgkin's lymphoma. Thromb Res 1999; 94: 131-134.